Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved Trial.
heart failure
sodium-glucose transporter 2 inhibitors
Journal
Circulation
ISSN: 1524-4539
Titre abrégé: Circulation
Pays: United States
ID NLM: 0147763
Informations de publication
Date de publication:
19 10 2021
19 10 2021
Historique:
pubmed:
31
8
2021
medline:
30
12
2021
entrez:
30
8
2021
Statut:
ppublish
Résumé
Empagliflozin reduces the risk of cardiovascular death or hospitalization for heart failure in patients with heart failure with preserved ejection fraction, but additional data are needed about its effect on inpatient and outpatient heart failure events. We randomly assigned 5988 patients with class II through IV heart failure with an ejection fraction of >40% to double-blind treatment with placebo or empagliflozin (10 mg once daily), in addition to usual therapy, for a median of 26 months. We prospectively collected information on inpatient and outpatient events reflecting worsening heart failure and prespecified their analysis in individual and composite end points. Empagliflozin reduced the combined risk of cardiovascular death, hospitalization for heart failure, or an emergency or urgent heart failure visit requiring intravenous treatment (432 versus 546 patients [empagliflozin versus placebo, respectively]; hazard ratio, 0.77 [95% CI, 0.67-0.87]; In patients with heart failure with preserved ejection fraction, empagliflozin produced a meaningful, early, and sustained reduction in the risk and severity of a broad range of inpatient and outpatient worsening heart failure events. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03057977.
Sections du résumé
BACKGROUND
Empagliflozin reduces the risk of cardiovascular death or hospitalization for heart failure in patients with heart failure with preserved ejection fraction, but additional data are needed about its effect on inpatient and outpatient heart failure events.
METHODS
We randomly assigned 5988 patients with class II through IV heart failure with an ejection fraction of >40% to double-blind treatment with placebo or empagliflozin (10 mg once daily), in addition to usual therapy, for a median of 26 months. We prospectively collected information on inpatient and outpatient events reflecting worsening heart failure and prespecified their analysis in individual and composite end points.
RESULTS
Empagliflozin reduced the combined risk of cardiovascular death, hospitalization for heart failure, or an emergency or urgent heart failure visit requiring intravenous treatment (432 versus 546 patients [empagliflozin versus placebo, respectively]; hazard ratio, 0.77 [95% CI, 0.67-0.87];
CONCLUSIONS
In patients with heart failure with preserved ejection fraction, empagliflozin produced a meaningful, early, and sustained reduction in the risk and severity of a broad range of inpatient and outpatient worsening heart failure events. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03057977.
Identifiants
pubmed: 34459213
doi: 10.1161/CIRCULATIONAHA.121.056824
pmc: PMC8522627
doi:
Substances chimiques
Benzhydryl Compounds
0
Glucosides
0
Sodium-Glucose Transporter 2 Inhibitors
0
empagliflozin
HDC1R2M35U
Banques de données
ClinicalTrials.gov
['NCT03057977']
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1284-1294Commentaires et corrections
Type : CommentIn
Références
Eur J Heart Fail. 2019 Oct;21(10):1279-1287
pubmed: 31523904
J Am Coll Cardiol. 2017 Feb 7;69(5):556-569
pubmed: 28153111
J Card Fail. 2020 Dec;26(12):1050-1059
pubmed: 32750486
Diabetes Obes Metab. 2014 Nov;16(11):1087-95
pubmed: 24939043
J Card Fail. 2020 Nov;26(11):977-984
pubmed: 32890737
N Engl J Med. 2019 Oct 24;381(17):1609-1620
pubmed: 31475794
Eur J Heart Fail. 2014 Sep;16(9):992-1001
pubmed: 25046483
J Am Heart Assoc. 2018 Apr 23;7(9):
pubmed: 29686028
Am Heart J. 2010 Oct;160(4):649-54
pubmed: 20934558
Circulation. 2020 Oct 27;142(17):1623-1632
pubmed: 32883108
N Engl J Med. 2020 Oct 8;383(15):1425-1435
pubmed: 32966714
Stat Med. 2016 Jun 15;35(13):2195-205
pubmed: 26751714
JACC Heart Fail. 2016 Sep;4(9):749-55
pubmed: 27179830
J Am Coll Cardiol. 2006 Apr 18;47(8):1603-11
pubmed: 16630997
N Engl J Med. 2020 Oct 8;383(15):1436-1446
pubmed: 32970396
Circulation. 2021 Jan 26;143(4):326-336
pubmed: 33081531
JACC Basic Transl Sci. 2019 Sep 04;4(5):575-591
pubmed: 31768475
JAMA Cardiol. 2021 May 1;6(5):499-507
pubmed: 33595593
Circulation. 2021 Oct 12;144(15):1193-1195
pubmed: 34459212
Circulation. 2017 Jul 4;136(1):6-19
pubmed: 28381470
Circulation. 2020 Feb 25;141(8):704-707
pubmed: 31707794
Circulation. 2018 Jul 31;138(5):458-468
pubmed: 29526832
Circulation. 2016 Jun 7;133(23):2254-62
pubmed: 27143684
N Engl J Med. 2019 Jun 13;380(24):2295-2306
pubmed: 30990260
ESC Heart Fail. 2020 Oct;7(5):2098-2112
pubmed: 32618139
Eur J Heart Fail. 2002 Jun;4(3):243-7
pubmed: 12034147
N Engl J Med. 2021 Jan 14;384(2):117-128
pubmed: 33200892
N Engl J Med. 2021 Oct 14;385(16):1451-1461
pubmed: 34449189
Diabetes Ther. 2018 Apr;9(2):863-871
pubmed: 29488164
N Engl J Med. 2021 Jan 14;384(2):129-139
pubmed: 33200891
JACC Heart Fail. 2018 Aug;6(8):633-639
pubmed: 29525327
Circulation. 2019 May 28;139(22):2528-2536
pubmed: 30882238
J Am Soc Nephrol. 2021 Jul;32(7):1616-1629
pubmed: 33846238
Nephrology (Carlton). 2019 Sep;24(9):904-911
pubmed: 30578654
JACC Heart Fail. 2021 May;9(5):374-382
pubmed: 33839075
Eur J Heart Fail. 2020 Sep;22(9):1551-1567
pubmed: 32441863
Am J Med. 2021 Apr;134(4):e241-e251
pubmed: 33127370
Eur J Heart Fail. 2014 May;16(5):560-5
pubmed: 24578164
Circ Heart Fail. 2020 Jul;13(7):e006720
pubmed: 32580655
Circulation. 2020 Sep 15;142(11):1040-1054
pubmed: 32673497
Pharmacol Res. 2020 Jul;157:104781
pubmed: 32360273
Eur Heart J. 2016 May 14;37(19):1526-34
pubmed: 26819227